Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 143

1.

Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.

Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B, Weidemann F, Wichmann O, Karch A, Mikolajczyk RT.

BMC Med. 2018 Jan 9;16(1):3. doi: 10.1186/s12916-017-0983-5.

2.

Moving forward on strengthening and sustaining National Immunization Technical Advisory Groups (NITAGs) globally: Recommendations from the 2nd global NITAG network meeting.

MacDonald NE, Duclos P, Wichmann O, Henaff L, Harnden A, Alshammary A, Tijerino RA, Hall M, Sacarlal J, Singh RR.

Vaccine. 2017 Dec 15;35(50):6925-6930. doi: 10.1016/j.vaccine.2017.10.048. Epub 2017 Nov 2.

3.

PRECEPT: an evidence assessment framework for infectious disease epidemiology, prevention and control.

Harder T, Takla A, Eckmanns T, Ellis S, Forland F, James R, Meerpohl JJ, Morgan A, Rehfuess E, Schünemann H, Zuiderent-Jerak T, de Carvalho Gomes H, Wichmann O.

Euro Surveill. 2017 Oct;22(40). doi: 10.2807/1560-7917.ES.2017.22.40.16-00620.

4.

Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.

Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon IK, Hombach J.

Vaccine. 2017 Oct 9;35(42):5535-5542. doi: 10.1016/j.vaccine.2017.08.066. Review.

5.

Cost-effectiveness of human papillomavirus vaccination in Germany.

Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Deleré Y, Ultsch B, Wichmann O, Krämer A, Greiner W.

Cost Eff Resour Alloc. 2017 Sep 4;15:18. doi: 10.1186/s12962-017-0080-9. eCollection 2017.

6.

Marked Underreporting of Pertussis Requiring Hospitalization in Infants as Estimated by Capture-Recapture Methodology, Germany, 2013-2015.

Schielke A, Takla A, von Kries R, Wichmann O, Hellenbrand W.

Pediatr Infect Dis J. 2018 Feb;37(2):119-125. doi: 10.1097/INF.0000000000001698.

PMID:
28723872
7.

Factors associated with parental acceptance of seasonal influenza vaccination for their children - A telephone survey in the adult population in Germany.

Boes L, Boedeker B, Schmich P, Wetzstein M, Wichmann O, Remschmidt C.

Vaccine. 2017 Jun 27;35(30):3789-3796. doi: 10.1016/j.vaccine.2017.05.015. Epub 2017 May 27.

PMID:
28558985
8.

Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.

Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A, Hengel H, Wichmann O, Poethko-Müller C.

BMC Infect Dis. 2017 May 19;17(1):356. doi: 10.1186/s12879-017-2461-2.

9.

Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015.

Rieck T, Feig M, An der Heiden M, Siedler A, Wichmann O.

Euro Surveill. 2017 Apr 27;22(17). pii: 30521. doi: 10.2807/1560-7917.ES.2017.22.17.30521.

10.

Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.

Harder T, Koch J, Wichmann O, Hellenbrand W.

J Infect. 2017 Aug;75(2):81-94. doi: 10.1016/j.jinf.2017.05.001. Epub 2017 May 6. Review.

PMID:
28487177
11.

Risk of Intussusception After Rotavirus Vaccination.

Koch J, Harder T, von Kries R, Wichmann O.

Dtsch Arztebl Int. 2017 Apr 14;114(15):255-262. doi: 10.3238/arztebl.2017.0255.

12.

Is the impact of childhood influenza vaccination less than expected: a transmission modelling study.

Weidemann F, Remschmidt C, Buda S, Buchholz U, Ultsch B, Wichmann O.

BMC Infect Dis. 2017 Apr 11;17(1):258. doi: 10.1186/s12879-017-2344-6.

13.

[What you always wanted and ought to know about measles].

Wicker S, Wichmann O, Matysiak-Klose D.

MMW Fortschr Med. 2017 Apr;159(6):54-58. doi: 10.1007/s15006-017-9484-x. Review. German. No abstract available.

PMID:
28374363
14.

Systematic identification of phosphorylation-mediated protein interaction switches.

Betts MJ, Wichmann O, Utz M, Andre T, Petsalaki E, Minguez P, Parca L, Roth FP, Gavin AC, Bork P, Russell RB.

PLoS Comput Biol. 2017 Mar 27;13(3):e1005462. doi: 10.1371/journal.pcbi.1005462. eCollection 2017 Mar.

15.

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.

Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C.

PLoS One. 2017 Jan 6;12(1):e0169368. doi: 10.1371/journal.pone.0169368. eCollection 2017. Review.

16.

Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.

Remschmidt C, Harder T, Wichmann O, Bogdan C, Falkenhorst G.

BMC Infect Dis. 2016 Nov 25;16(1):711. Review.

17.

Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany.

Falkenhorst G, Remschmidt C, Harder T, Wichmann O, Glodny S, Hummers-Pradier E, Ledig T, Bogdan C.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Dec;59(12):1623-1657. German. No abstract available.

PMID:
27885449
18.

Hintergrundpapier der STIKO: Evaluation der bestehenden Influenzaimpfempfehlung für Indikationsgruppen und für Senioren (Standardimpfung ab 60 Jahren).

Remschmidt C, Harder T, Wichmann O, Garbe E, Ledig T, Terhardt M, Wicker S, Zepp F, Mertens T.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Dec;59(12):1606-1622. German. No abstract available.

PMID:
27815578
19.

[Recommendations for vaccinations in adults : Evidence and challenges of implementation].

Wichmann O, Schaade L.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Dec;59(12):1541-1543. German. No abstract available.

PMID:
27807603
20.

Use of existing systematic reviews for evidence assessments in infectious disease prevention: a comparative case study.

Harder T, Remschmidt C, Haller S, Eckmanns T, Wichmann O.

Syst Rev. 2016 Oct 11;5(1):171. Review.

Supplemental Content

Loading ...
Support Center